Trial reportJournal of cosmetic dermatology2026
Rapid, Strong, and Visible Efficacy of a Dermocosmetic in Acne Patients With Dark Skin Phototypes: Results of a Randomized Split-Face Study.
Trial report in Journal of cosmetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
INTRODUCTION AND
objectivesAcne is a chronic inflammatory skin disease that can cause acne-induced hyperpigmentation (AIH), especially in subjects with phototype IV and above (hereafter darker skin tones). This study evaluated the efficcay kinetics of a dermocosmetic cream (DC cream) in adults with darker skin phototypes and mild to moderate acne. MATERIAL AND
methodsAn intra-individual, randomized, split face, single centre 57 day-study was conducted in 16 adults with dark skin tones (phototype IV, V and VI) and mild-to-moderate acne. DC cream was applied 2/day on one hemiface. Assessments included total, inflammatory and non-inflammatory lesion counts, AIH intensity and darkness severity, PAHPI score and local tolerance. Subjects rated the perceived benefits of DC cream.
results75% of subjects were women, mean age was 26.8 ± 6.7 years; 50% had phototype IV, 31.2% phototype V, and 18.8% phototype VI. 68.8% had mild (GEA 2) and 31.2% moderate (GEA 3) acne. The total lesion count significantly decreased from Day 5 (-17.1%; p < 0.05) until Day 57 (-44.9%; p < 0.01) on the DC-treated side versus - 28.4% on the untreated side at Day 57. Inflammatory and non-inflammatory lesion counts significantly (p < 0.01) decreased from Day 11 to Day 57 with DC cream. AIH marks intensity significantly (p < 0.01) decreased starting Day 11 until Day 57; as did the PAHPI score (-22.7%) after 57 days with hemi-face differences being significantly (p < 0.05) in favor of DC cream. AIH darkness severity significantly improved with DC cream, with no changes on the untreated side. DC cream was highly appreciated and very well tolerated by the subjects.
conclusionsThis clinical study provides strong evidence on the efficacy kinetics of a DC cream in acne management in subjects with dark skin tones. It shows that early, daily and specific treatment with a targeted DC significantly improves all acne lesions type, as well as AIH marks as soon as 11 days of use, in addition to exhibiting high patient satisfaction rates and excellent tolerability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.